Genentech has announced positive topline results from its Phase III studies, TENAYA and LUCERNE, evaluating its new drug faricimab, for people with wet (neovascular) age-related macular degeneration (nAMD). Both studies have shown that people receiving faricimab injections at fixed intervals of up to every 16 weeks achieved visual acuity outcomes as effective as those receiving [Read More]
Category: Latest News
How well are you adapting to visual impairment?
How can you tell if you are adapting as well as possible to the most important facets of your everyday life? A new self-survey is helping visually impaired and blind individuals score how well they are adapting. It is similar to a needs assessment questionnaire used by rehabilitation specialists, but it is designed for self- [Read More]
Lucentis Substitute In Phase 3 Trials
Samsung Bioepis is reporting first year results from their phase 3 study of a proposed lucentis biosimilar (SB11). A biosimilar is a biological product (derived from a living organism) that shows no clinically meaningful differences from another biologic (eg. Lucentis). This study has shown that, at 52 weeks, primary end points were met for visual [Read More]
Vitamin D3 and Omega-3 Offer No Protection Against AMD
Observational studies have suggested that higher intake or blood levels of vitamin D and marine omega-3 fatty acids may be associated with lower risks of age-related macular degeneration (AMD). A recent large randomized trial (VITAL), however, has concluded that supplementation with vitamin D3 and marine omega-3 fatty acids actually had no significant overall effect on [Read More]
Smoking and Wet AMD Treatment
It has long been known that cigarette smoking reduces levels of plasma antioxidant, which protects retinal cells. It is also suspected as a contributor to cataract formation, restriction of night vision, and amblyopia (“lazy eye”). As reported in the September 2020 issue of the journal, Retina, a research team has confirmed the effect of smoking [Read More]